Japan records surprise trade deficit in July as exports weaken further
Director John Hernandez of ResMed INC (NASDAQ:RMD), a $41.65 billion medical equipment company trading near its 52-week high of $293.08, sold 2,575 shares of company stock on August 18, 2025. The shares were sold at prices ranging from $286.90 to $287.24, netting approximately $739,289. According to InvestingPro analysis, ResMed maintains a "GREAT" financial health score, supported by strong liquidity metrics.
On the same day, Hernandez also exercised options to acquire 2,575 shares of ResMed common stock at a price of $148.90, for a total value of $383,417. Following these transactions, Hernandez directly owns 4,045 shares of ResMed. The stock currently trades at a P/E ratio of 29.88, and InvestingPro subscribers have access to 13 additional key insights about ResMed’s valuation and growth prospects through the comprehensive Pro Research Report.
In other recent news, ResMed Inc (NYSE:RMD). reported its fourth-quarter earnings for fiscal year 2025, showcasing a robust performance in earnings per share (EPS) but falling short on revenue expectations. The company achieved an EPS of $2.55, surpassing the forecasted $2.48. However, ResMed’s actual revenue was $1.3 billion, slightly below the anticipated $1.33 billion. This represents a 23% increase in non-GAAP diluted EPS and a 10% rise in group revenue compared to previous periods. Despite these positive earnings results, the company’s stock experienced a decline in aftermarket trading. These developments highlight the mixed financial outcomes for ResMed in the recent quarter. Investors and analysts may find these figures significant as they assess the company’s financial health.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.